Dr. Timothy Mackey, an Assistant Professor at the University of California in San Diego, alerts clinicians in his commentary appearing in the June 2016 issue of Mayo Clinic Proceedings to a legal decision that has led to a shift in the ability of the FDA to regulate off-label drug prescribing, which could lead to an increased onslaught of pharmaceutical advertising and also create confusion in recognizing effective and poor options. Available at: [ Ссылка ]

свернуть